Many of these mechanisms remain unaddressed by existing treatments, limiting their overall effectiveness.
This unique approach enables us to tackle the complexity of solid tumours with unprecedented precision and maximum efficacy.
Via our human-centric and data-driven pre-clinical R&D pipeline, we are redefining cancer immunotherapy with RNA technology.
Loïc holds a PhD in Medicinal Chemistry and brings over 15 years of experience in therapeutic nucleic acid design, delivery, and development. He has successfully built and led preclinical R&D teams focused on advancing innovative therapeutics.
Steven is a serial CEO with over 25 years of experience, having successfully led three UK IPOs and orchestrated seven exits or mergers. His expertise encompasses RNA therapeutics, CMC, and a strong focus on licensing and financing strategies.
Robert holds a PhD in Immunology, Infection, and Inflammatory Disease. With over 7 years of experience in translational immuno-oncology research. He is an expert in the preclinical assessment of novel immunotherapies.
Andy holds a PhD in Pathology and spent 11 years as a Principal Investigator at the National Cancer Institute (NCI). He has since led multiple discovery-stage to Investigational New Drug (IND)-enabling studies, bringing extensive experience from several early-stage biotech ventures.
Before joining DSV, Laura served as Associate Director of Cancer Research UK’s Commercial Partnerships team, where she led the Strategic Alliances function to enhance the charity’s strategic drug discovery and platform collaborations with various commercial partners. During her 14 years at CRUK and Cancer Research Technology, she was involved in negotiating numerous significant licensing, collaboration, and spin-out agreements. Laura holds a first-class degree in Biochemistry and a PhD in cell signaling from the University of Bristol and has also gained experience in both academic and commercial research roles in the US and the UK.
CEO of Therapeutic Innovation at CRH, previously directing Cancer Research UK’s Therapeutic Discovery Labs for 14 years. He successfully transitioned their translational strategy to a collaborative model that connects industry partners with academic researchers from the initial target selection stages. With over 20 years of experience in biopharma, including a role as Research Director at Spain's largest pharmaceutical company, Almirall, he has led efforts that resulted in over 30 candidate drugs for regulatory development, including two marketed therapies. Hamish holds a degree in natural sciences and a PhD in organic chemistry from the University of Cambridge.
Professor Doreen Cantrell is a world-renowned immunologist specializing in T cell biology. She is a Wellcome Trust Principal Research Fellow at the University of Dundee, where she leads pioneering research on T lymphocyte signaling pathways, metabolism, and differentiation. Her work integrates biochemistry, cell biology, and molecular genetics to unravel the mechanisms that regulate immune responses. Professor Cantrell's significant contributions to the field have earned her numerous prestigious recognitions, including being appointed a Commander of the Order of the British Empire (CBE) and being elected as a Fellow of the Royal Society and the Royal Society of Edinburgh.
Professor Rahul Roychoudhuri is a leading expert in cancer immunology and immunotherapy, currently serving at the Department of Pathology, University of Cambridge. His research focuses on uncovering the molecular and cellular mechanisms that regulate T-cell function and tumor immunosuppression. Notably, his work on the transcription factor BACH2 has provided crucial insights into immune homeostasis and cancer immunotherapy. Professor Roychoudhuri has been awarded a Sir Henry Dale Fellowship and a Lister Institute Research Prize for his groundbreaking research in this field.
Kevin Maskell is the Research Director and Co-Founder of Bioarchitech, a company dedicated to developing innovative immunotherapies. With over 18 years of experience in translational immunology and oncology, Kevin has made substantial contributions to cancer vaccine development and anti-tumor T cell research. His previous roles include serving as a Senior Scientist at Oxford Cancer Biomarkers and managing biomarker laboratories internationally. Kevin's work focuses on advancing the immunotherapy pipeline at Bioarchitech, aiming to improve cancer treatments through cutting-edge research and development.